<DOC>
	<DOC>NCT00791739</DOC>
	<brief_summary>The study has a double purpose: a first phase intends to assess the effectiveness and tolerability of trazodone, an antidepressant with sedative and sleep-promoting properties, in the treatment of fibromyalgia; a second phase intends to evaluate if the addition of pregabalin to patients who have shown a partial response to trazodone additionally improves fibromyalgia symptomatology.</brief_summary>
	<brief_title>Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria written, informed consent able to understand and comply with the requirements of the study pregnancy or breastfeeding unwillingness to discontinue other prescribed medications before entering in the study patients who had previously received trazodone without improvement or who did not tolerate the drug patients who had previously received pregabalin without improvement or who did not tolerate the drug (only for the phase II of the study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>trazodone</keyword>
	<keyword>pregabalin</keyword>
	<keyword>Fibromyalgia Impact Questionnaire (FIQ)</keyword>
	<keyword>Pittsburgh Sleep Quality Inventory (PSQI)</keyword>
	<keyword>Brief Pain Inventory (BPI)</keyword>
</DOC>